Close
More
 
back_btn_arrow   Go back
Sign up or login to continue
New to Univadis?
Univadis is a free service for United States Healthcare Professionals.
*Please fill in all required fields.
By clicking "Sign up", I agree to the Terms of Use and Privacy Policy. and attest I am a healthcare professional.
Existing Univadis member:
Sign up or login to continue
Make more time for the moments that matter. Get expertly-curated updates and medical education, instantly.
New to Univadis?
Simply enter a password to join for free, if the information below is correct.
 
*Please enter a valid email address and password.
By clicking "Sign up", I agree to the Terms of Use and Privacy Policy. and attest I am a healthcare professional.
Forgot your password?  Reset now
Existing Univadis member:
Please login to continue
Welcome! Great to have you back.
*Your email address or password is incorrect.
Forgot your password?  Reset now
Reset your password
Please enter your email address, and we will send you a link to reset your password.
*Please enter a valid email address.

is already registered on Univadis

Is this you? Enter your password to continue.
The password you entered is incorrect. Please try again or choose a different option.
Forgot your password?  Reset now
Need more help? Please contact Member Service at support@univadis.com

is already registered on Univadis

Need more help? Please contact Member Service at support@univadis.com
Instructions to create a new password have been sent to the following email address:

For further assistance, please Contact Member Support
Thanks for Registering.
BreadCrumbsIncluded hideAllBreadCrumbs
European Association for the Study of Diabetes
Barcelona, Spain, September 16-20, 2019
News Coverage
Essential conference news
Vildagliptin shows promise for increasing time to treatment failure.
September 24, 2019
Patients with T2D are at risk of poorly controlled disease.
September 24, 2019
Pharmacological strategies are needed to help reduce excess glycogen in patients with T2D.
September 24, 2019
Also preserves postprandial insulin secretion.
September 23, 2019
Can this new long-acting GLP-1 receptor agonist change T2D practice?
September 23, 2019
Can ultra rapid lispro be the game-changer in T1D?
September 23, 2019
Injection vs inhalation — which insulin is best?
September 23, 2019
Semaglutide vs liraglutide — which should you choose?
September 20, 2019
Escalating tirzepatide doses may result in improved gastrointestinal-related tolerability.
September 20, 2019
Metformin and insulin are the only currently approved agents for children and adolescents with T2D.
September 20, 2019
Some individuals with T1D have difficulties achieving glycemic control using insulin lispro alone.
September 20, 2019
Less than one-third of patients with T1D have disease that is optimally controlled.
September 19, 2019
Almost half of patients with T1D are overweight or obese.
September 19, 2019
Is faster insulin aspart a feasible option for earlier glucose control?
September 19, 2019
Semaglutide and canagliflozin — which one is better for T2D?
September 19, 2019
Diabetes specialists presented thousands of studies at this year’s EASD meeting. Univadis journalists chose the most clinically relevant ones and summarized them in our easy-to-scan bullet-point format.

Univadis is a free, time-saving medical news & education community designed exclusively for healthcare professionals. Unique executive summaries tame the onslaught of medical literature and keep clinicians up to date in just a few minutes per day. Concise, interactive educational presentations from our experts help clinicians stay on top of practice-changing research and trends, and collaborate with colleagues at any time, on any device.

Aptus Health does not endorse and is not responsible for the accuracy of the content, or for practices or standards of non-Aptus Health sources.

Copyright © 2019 Aptus Health, Inc. All rights reserved. Version 2.14.541.14

Contact Us

(888) 729-4546
Monday - Friday 8am to 7pm ET

support@univadis.com